Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
The role of tumour markers in ovarian cancer
G. Gargano1,*, M. Correale2, I. Abbate2, G. Falco1, N. De Frenza1, Lorusso3, M. De Lena3, A. De Leonardis1
Show Less
1
Division of Gynaecological Oncology, Institute of Bari
2
Clinical Chemistry Laboratory, RIA Unit
3
Division of Medical Oncology Oncology Institute of Bari (Italy)
Clin. Exp. Obstet. Gynecol. 1990, 17(1), 23–29;
Published: 10 March 1990
Abstract
In the present review, the Authors have evaluated the current status of the utilization of the principle tumor markers for ovarian carcinoma in clinical gynecological practice. The major difficulty in individualizing a single marker is represented by the histological differentiation of the tumor itself. In fact, whereas for the malignant germ cell tumors, useful markers (AFP, B-HCG) are already available, for other histological forms, valid markers have been identified only because of the availability of the monoclonal antibody: CA 125. Even if this marker cannot be proposed for mass screening, it represents a useful instrument for the diagnosis and monitoring of ovarian carcinoma. The serum levels are well correlated with the clinical status of the patient and high concentrations of the marker are strongly indicative of disease progression at the second-look. Numerous other markers such as NB 70K, IAP, PLAP, CA 15-3 and TAG 72, are actually in the clinical evaluation phase, for the most part in association with CA 125.
Keywords
Markers
CA 125
Ovarian Cancer